FDA panel to review Qnexa in February 2012
MOUNTAIN VIEW, Calif. — The Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee is set to review an investigational treatment for obesity.
Biopharmaceutical company Vivus said the panel will review its new drug application for Qnexa on Feb. 22, 2012.
Meanwhile, the FDA will complete its review of the NDA for Qnexa on April 17, 2012. The regulatory agency accepted the NDA in November after Vivus' resubmission of the NDA in October.